Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sino-U.S. To Jointly Set Up Medical Device R&D Base In Shenzhen

This article was originally published in PharmAsia News

Executive Summary

Shenzhen Institute of Advanced Technology, a branch of the Chinese Academy of Sciences, and American medical device company STI Medical Systems will jointly set up a high-level medical device R&D base in Shenzhen. The collaboration will focus on five areas: (1) STI will invest in SIAT and set up the R&D facility; (2) STI and SIAT will jointly apply for research grants from the U.S. National Science Foundation, National Institutes of Health and the U.S. FDA; (3) SIAT may send its students for internships in the U.S; (4) both organizations will incorporate their funding, technology, talent and facilities as well as research management experience; and (5) both will establish an integrated industry application laboratory and possibly a joint venture firm when future conditions are ripe. (Click here for more - Chinese Language)

You may also be interested in...



UK’s CMA Issues Fines Over Fludrocortisone

The UK’s CMA has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.

Coronavirus Update: Moderna Set For Bigger Test As Vaccine Trials Begin In Older People

Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.

Montefarmaco Eyes Expansion In Italy And Overseas Through IPO

Italian OTC and supplements player Montefarmaco is preparing to list on AIM Italia to raise funds for M&A and further international expansion.

UsernamePublicRestriction

Register

LL025498

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel